ERBB2 and invasive breast carcinoma: The results of our IHC panel divided the patients with HR-positive and HER2-negative invasive breast cancers into 2 distinct prognostic subtypes, those with favorable-phenotype (Ki67 LI-low and p53-negative) and unfavorable-phenotype group (Ki67 LI-high and/or p53-positive) tumors.